Internal Medicine, Endocrinology, Diabetes, & Metabolism · Little Rock, AR
NPI
1619133519
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
10001 Lile Dr
Little Rock, AR, 72205
Phone (501) 227-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$358K
17,074 services
Medicare patients, 2024
671
Average age 72
Drug cost, 2024
$4.7M
11,287 prescriptions
Company payments, 2025
$13K
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shunzhong S Bao was code J0897 (injection, denosumab, 1 mg), 2,640 times for 26 patients. In total Shunzhong S Bao billed 17,074 services in 101 codes, and Medicare paid $358K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 2,640 | 26 | $20.59 | $54K |
| 99214 Office E&M - Established | Office | 1,641 | 640 | $83.09 | $136K |
| 36415 Venipuncture Blood Collection | Office | 1,396 | 605 | $8.62 | $12K |
| 80053 Clinical Chemistry | Office | 1,197 | 582 | $10.26 | $12K |
| 83036 Blood Count | Office | 1,156 | 552 | $9.48 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,028 | 516 | $11.32 | $12K |
| 84443 Clinical Chemistry | Office | 1,008 | 552 | $16.39 | $17K |
| 80061 Clinical Chemistry | Office | 933 | 495 | $13.01 | $12K |
| 84481 Clinical Chemistry | Office | 724 | 433 | $16.53 | $12K |
| 84439 Clinical Chemistry | Office | 706 | 427 | $8.80 | $6,215 |
| 82043 Clinical Chemistry | Office | 630 | 327 | $5.62 | $3,542 |
| 82570 Clinical Chemistry | Office | 621 | 325 | $5.05 | $3,137 |
| 95251 Test - Miscellaneous | Office | 435 | 155 | $24.02 | $10K |
| 82306 Clinical Chemistry | Office | 302 | 245 | $28.93 | $8,736 |
| 85025 Blood Count | Office | 257 | 213 | $7.61 | $1,956 |
By year: 2022 $335K for 15,528 services; 2023 $361K for 16,479 services; 2024 $358K for 17,074 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,396 | 605 | $8.62 | $12K |
| 80053 Clinical Chemistry | 1,197 | 582 | $10.26 | $12K |
| 83036 Blood Count | 1,156 | 552 | $9.48 | $11K |
| 84443 Clinical Chemistry | 1,008 | 552 | $16.39 | $17K |
| 80061 Clinical Chemistry | 933 | 495 | $13.01 | $12K |
| 84481 Clinical Chemistry | 724 | 433 | $16.53 | $12K |
| 84439 Clinical Chemistry | 706 | 427 | $8.80 | $6,215 |
| 82043 Clinical Chemistry | 630 | 327 | $5.62 | $3,542 |
| 82570 Clinical Chemistry | 621 | 325 | $5.05 | $3,137 |
| 82306 Clinical Chemistry | 302 | 245 | $28.93 | $8,736 |
Medicare prescription drug claims, 2024
In 2024, the drug Shunzhong S Bao prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,359 prescriptions and refills. In total Shunzhong S Bao wrote 11,287 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,359 | 2,373 | 231 | $10K |
| Ozempic Semaglutide | 1,258 | 1,530 | 222 | $1.4M |
| Jardiance Empagliflozin | 699 | 1,004 | 129 | $585K |
| Atorvastatin Calcium Generic | 374 | 797 | 97 | $3,053 |
| Trulicity Dulaglutide | 326 | 387 | 60 | $374K |
| Metformin Hcl Er Metformin Hcl | 308 | 484 | 71 | $2,367 |
| Metformin Hcl Generic | 289 | 516 | 63 | $2,176 |
| Mounjaro Tirzepatide | 250 | 259 | 43 | $269K |
| Acarbose Generic | 241 | 377 | 52 | $7,631 |
| Synthroid Levothyroxine Sodium | 237 | 430 | 45 | $15K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 227 | 371 | 52 | $24K |
| Kerendia Finerenone | 223 | 257 | 32 | $166K |
| Ezetimibe Generic | 208 | 424 | 50 | $3,275 |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 196 | 247 | 33 | $199K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 194 | 287 | 44 | $76K |
Brand drugs: 6,342 claims; generic drugs: 4,240 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shunzhong S Bao $13K ($13K in general payments such as food, travel and fees) from 32 companies. The largest payer was CeQur Corporation with $6,980.
| Company | Payments | Amount |
|---|---|---|
| CeQur Corporation | 2 | $6,980 |
| Medtronic, Inc. MDT | 12 | $1,219 |
| Novo Nordisk Inc NVO | 14 | $722 |
| Beta Bionics, Inc. BBNX | 8 | $418 |
| Alexion Pharmaceuticals, Inc. AZN | 4 | $414 |
| Sequel Med Tech, LLC | 5 | $385 |
| Insulet Corporation PODD | 7 | $342 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 12 | $334 |
| Abbvie Inc. ABBV | 8 | $293 |
| Corcept Therapeutics CORT | 11 | $273 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.